



# CAMA

Corporate Alliance on Malaria in Africa

# News Update

## Note from the CEO

Powered by  ABCHealth

CAMA Office

As the first quarter of 2026 unfolds, it is an opportunity to reflect on how far we have come and, more importantly, to look ahead with renewed purpose. The fight against malaria continues to demand urgency, innovation, and collaboration. While significant progress has been made over the years, the challenges before us remind us that our collective work is far from over. This year, we recommit ourselves to accelerating impact, strengthening partnerships, and advancing practical solutions that bring us closer to a malaria-free Africa.

Our goals for the year are ambitious but necessary. We aim to deepen private-sector engagement, strengthen strategic partnerships, and scale interventions that deliver measurable results. Through the Corporate Alliance on Malaria in Africa (CAMA), we will continue to champion innovative approaches, amplify knowledge exchange, and support initiatives that translate strategy into real impact in communities and workplaces. We also look forward to expanding our coalition, strengthening collaboration across sectors, and ensuring that the private sector plays a more structured and visible role in malaria prevention and elimination efforts.

This year will also be defined by action. From thought-leadership platforms and strategic dialogues to on-the-ground interventions and workplace programmes, our focus will remain on ensuring that every effort contributes meaningfully to the broader goal of malaria elimination. We are particularly excited about the opportunities to harness new technologies, strengthen data-driven decision making, and foster partnerships that bring innovation closer to the communities that need it most.

As we move forward, our success will depend on the continued commitment of our members, partners, and stakeholders. Your engagement, expertise, and

leadership remain the driving force behind the progress we seek to achieve. I encourage every member of our coalition to remain actively involved, share knowledge, contribute ideas, and participate in the initiatives that will shape our collective impact this year.

We are also looking forward to our **World Malaria Day Webinar** in **April 2026**, which will bring together leaders from across the private sector, global health institutions, and innovation partners to explore critical conversations around the future of malaria prevention and control. This will be an important moment for dialogue, knowledge sharing, and collaboration. I warmly invite all our members and partners to be part of this conversation as we collectively examine new ideas, share experiences, and strengthen our shared commitment to malaria elimination.

Together, we have the opportunity to make meaningful progress in reducing the burden of malaria and improving the health and productivity of communities across Africa. I look forward to the work ahead and to the continued collaboration that makes this mission possible.

*“Accelerating malaria elimination requires structured private sector engagement, data-driven decision-making, and cross-sector collaboration that translates strategy into measurable impact across communities and workplaces.”*


**Dr. Mories Atoki**

CEO, ABCHealth  
Lead, CAMA Office



# Malaria News Update

## [New Malaria Drug Could Crush Resistance and Stop the Deadly Spread—Here's How](#)



A revolutionary antimalarial, MK-7602, shows promise against malaria by targeting the parasite at multiple life stages. Developed by WEHI and Merck (MSD), it blocks two critical enzymes, reducing the risk of resistance. Preclinical tests in mice and human blood cells show it can disrupt blood, liver, and transmission stages. Early clinical trials confirm safety and tolerability. With malaria still killing 600,000 people annually—mostly children under five—MK-7602 offers hope for a powerful new tool to treat infections and curb global transmission.

## [Malaria Breakthrough: New Drug Hits 97% Cure Rate and Offers Hope for Kids](#)



A late-stage trial of GanLum, developed by Novartis and Medicines for Malaria Venture, shows a 97.4% cure rate—surpassing current treatments. Combined with vaccines like Mosquirix and R21/Matrix-M, malaria deaths have declined significantly. Continued innovation, access, and global collaboration could accelerate progress toward eradication and save hundreds of thousands of lives annually.

## [Malaria Breakthroughs Offer Hope: Vaccines, Antibodies, and Baby-Safe Treatments](#)



Malaria, responsible for over 600,000 deaths annually, mostly in children under five—faces rising drug resistance. However, vaccines like Mosquirix and R21/Matrix-M, along with innovations such as the MAD21-101 antibody and infant-friendly treatments like Coartem Baby, are improving prevention and care. Combined with genetic surveillance tracking resistance, these advances are bringing malaria-free childhoods closer to reality.

## [NIH Scientists Uncover Hidden Weak Spot in Malaria Parasite—A Game-Changer for Prevention](#)



Researchers at the National Institutes of Health have identified a new class of antibodies, including MAD21-101, that target a previously untapped region of the malaria parasite (pGlu-CSP). In studies against *Plasmodium falciparum*, these antibodies blocked infection, highlighting strong potential for prevention.

## [Nigerian Scientists Crack Key Malaria Enzyme, Paving Way for Next-Gen Drugs](#)



A Nigerian-led team at Obafemi Awolowo University, led by Olatomide Fadare, has mapped the first crystal structure of *Plasmodium falciparum* transketolase. This enables targeted drug design, with promising antimalarial candidates already identified, and highlights Nigeria's growing role in globally competitive scientific research.

## [Climate Change Could Trigger 123 Million More Malaria Cases in Africa by 2050](#)

New research suggests climate change could dramatically worsen malaria in Africa, adding about 123 million cases and over 532,000 deaths between 2024 and 2050 if current control efforts remain unchanged. Analyzing 25 years of data on climate, malaria control, socioeconomic factors, and extreme weather, scientists found that extreme weather events, such as floods and heatwaves, are the biggest drivers of increased risk, responsible for most projected cases and deaths. Rather than spreading to new regions, malaria is expected to intensify in already endemic areas.

## Envu Advances Smarter Vector Control with Dual-Action Innovation



Envu highlights the importance of smarter insecticide use in strengthening malaria vector control. Rather than relying on the idea of “stronger” chemicals, effective control depends on choosing safe, targeted solutions and managing insecticide resistance. One innovation, Fludora® Fusion for Indoor Residual Spraying, combines two active ingredients—clothianidin and deltamethrin—to improve mosquito control and slow resistance development. Studies show the dual-action formulation kills mosquitoes faster and prevents resistance seen with single-ingredient products. Envu emphasizes that strong stewardship, proper training, and accurate resistance testing remain essential to ensure these tools continue protecting communities and supporting long-term malaria control efforts.



### Chevron Supports Push for Country-Led Malaria Control

Chevron supports the new report “Making Country-Led Malaria Control a Reality,” which calls for shifting leadership and ownership of malaria programs to governments in endemic countries. By strengthening local institutions, unlocking domestic financing, and enhancing accountability, the approach aims to build sustainable malaria responses and accelerate progress toward elimination.



### Vestergaard & Harvestfield Break Ground on Innovative Mosquito Net Facility in Ogun State.

Vestergaard Sàrl and Harvestfield Industries Limited have marked a historic milestone with the launch of SNG Health, a first-of-its-kind joint venture in Nigeria. The facility will manufacture PermaNet Dual, Vestergaard's latest dual active-ingredient mosquito net designed to combat insecticide resistance. Production is set to begin in April 2026, with an annual capacity of 10 million nets and the creation of 600 skilled jobs.

## MEMBERS OF THE ALLIANCE



## Join the Fight Against Malaria

The Corporate Alliance on Malaria in Africa is a coalition of companies with business interests in Africa. For over 16 years, CAMA members have led and supported innovative malaria prevention, control and treatment activities and collectively deployed workplace & community programs reaching over 200 million people. You too can take action - [join](#) the Coalition today and let us work together to fight Malaria in Africa

# Recent Activities Across the Coalition



The ABCHealth Academy for Health Entrepreneurs is a structured capacity-building programme designed to equip emerging health entrepreneurs across Africa with the knowledge and skills needed to develop scalable, efficient, and impactful health solutions. The programme runs through both Anglophone and Francophone tracks, ensuring inclusive participation, with English delivery supported by interpretation for Francophone participants. The Academy was formally inaugurated through induction ceremonies held in February 2026, with the Francophone cohort inducted on 26th February and the Anglophone cohort on 27th February, marking the official commencement of the learning journey for both groups.



Following a series of one-on-one engagements with each member, the Corporate Alliance on Malaria in Africa (CAMA) General Members Meeting served as a collective forum to consolidate insights, align priorities, and strengthen collaboration across the network.

The meeting provided an opportunity to reflect on key themes emerging from individual discussions, including member contributions, strategic focus areas, and opportunities for deeper engagement in malaria prevention and control efforts. It also reinforced the importance of coordinated action in advancing CAMA's shared mission across public and private sector partners.

## Key Upcoming Events



The Corporate Alliance on Malaria in Africa (CAMA) World Malaria Day Webinar is an upcoming high-level engagement focused on advancing innovative, technology-driven approaches to malaria prevention and control across Africa. The webinar, themed “Smart Vector Control for Workforce and Community Protection: Harnessing Technology to Strengthen LLIN and IRS Impact in Urban and Rural Settings,” will explore how digital tools, data systems, and emerging innovations can enhance the effectiveness of core vector control interventions such as Long-Lasting Insecticidal Nets (LLINs) and Indoor Residual Spraying (IRS). **REGISTER TO ATTEND.**



### ABCHealth at GITEX Future Health Africa 2026, Casablanca, Morocco

The ABCHealth high-level delegation will be participating in GITEX Future Health Africa, Morocco, scheduled to hold from 4–6 May 2026. This strategic engagement will convene global leaders, innovators, policymakers, and private sector stakeholders to explore the future of healthcare innovation, digital transformation, and resilient health systems across Africa. The forum will spotlight how emerging technologies—including artificial intelligence, digital health infrastructure, and data-driven solutions—can accelerate access, efficiency, and quality of healthcare delivery on the continent.

### ABCHealth at Africa Health ExConference 2026, Cairo, Egypt

The ABCHealth upcoming delegation at the Africa Health ExConference, scheduled to hold from 15–18 June 2026, will participate in one of the continent’s leading convenings on health systems strengthening, innovation, and private sector collaboration. The conference, themed “The Africa We Want,” will bring together key stakeholders across government, development partners, private sector actors, and innovators to deliberate on pathways toward a stronger, more resilient, and people-centered African health system.



### CAMA Malaria Spolpat Workshop - June 2026